Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis

Pediatrics International

Volumn 46, Issue 5, 2004, Pages 597-600

  Abe, Yoshifusa ^a   Tsuji, Yuichiro ^a   Hisano, Masataka ^a   Nakada, Masayuki ^a   Miura, Katsushi ^a   Watanabe, Shuichiro ^a   Odajima, Yasuhei ^a   Iikura, Yoji ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adolescent; Lupus nephritis; Mizoribine; Pharmacokinetics; Serum concentration

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; MIZORIBINE; PREDNISOLONE; STEROID;

ADOLESCENT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; ERYTHEMA; FEMALE; HERPES ZOSTER; HUMAN; HYPERURICEMIA; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTOXICITY; PRIORITY JOURNAL;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUPUS NEPHRITIS; RIBONUCLEOSIDES;

EID: 7044272754     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-200x.2004.01936.x     Document Type: Article

References (17)

1. Yoshioka K, Ohashi Y, Sakai T et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000; 58: 317-24.
2. Mizuno K, Tsujino M, Takeda M et al. Studies on bredinin. I. Isolation, characterization and biochemical properties. J. Antibiot. (Tokyo) 1974; 27: 775-82.
3. Homma M, Akizuki R, Yokohari R et al. Clinical evaluation of mizoribine on lupus nephritis: Multicenter single-blind comparative study with inactive placebo (in Japanese). Rinsho-Iyaku 1989; 5: 795-824.
4. Aihara Y, Miyamae T, Ito S et al. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr. Int. 2002; 44: 199-204.
5. Hamasaki T, Mori M, Kinoshita Y, Saeki T, Sakano T. Mizoribine in steroid-dependent nephrotic syndrome of childhood. Pediatr. Nephrol. 1997; 11: 625-7.
6. Nagaoka R, Kaneko K, Ohtomo Y, Yamashiro Y. Mizoribine treatment for childhood IgA nephropathy. Pediatr. Int. 2002; 44: 217-23.
7. Yumura W, Uchida K, Kawashima A et al. Evaluation of plasma concentration of mizoribine as an immunosuppressive agent in lupus nephritis patients (in Japanese). Kidney Dialysis 1999; 47: 705-8.
8. Takada K, Nakae H, Asada S, Ichikawa Y, Fukunishi T, Sonoda T. Rapid method for the high-performance liquid chromatographic determination of bredinin in human serum. J. Chromatogr. 1981; 222: 156-9.
9. Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr. Int. 2002; 44: 196-8.
10. Okamoto K, Ito M, Suzuki Y. Studies on antinephritic effect of mizoribine (p-INN, Bredinin), a new immunosuppressive agent, and azathioprine (1) effect on the nephrotic type of anti-GBM nephritis in rats. Japan. J. Pharmacol. 1983; 33: 541-8.
11. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosupressive drug mizoribine. J. Clin. Invest. 1991; 87: 940-8.
12. Hirohata S, Nakanishi K, Yanagida T. Inhibition of cyclin A gene expression in human B cells by an immunosuppressant mizoribine. Clin. Exp. Immunol. 2000; 120: 448-53.
13. Kobayashi Y, Shigematsu H, Masaki Y. Modification of crescentic masugi nephritis in the rabbit by bredinin, a new immunosuppressant. Virchows Arch. [Cell Pathol.] 1983; 43: 103-19.
14. Honda M. Nephrotic syndrome and mizoribine in children. Pediatr. Int. 2002; 44: 210-6.
15. Sonda K, Takahashi K, Tanabe K et al. Clinical pharmaco-kinetic study of mizoribine in renal transplantation patients. Transplant. Proc. 1996; 28: 3643-8.
16. Takada K, Asada S, Ichikawa Y et al. Pharmacokinetics of bredinin in renal transplant patients. Eur. J. Clin. Pharmacol. 1983; 24: 457-61.
17. Zaoui P, Serre-Debeauvais F, Bayle F et al. Clinical use of mizoribine (Bredinin) and pharmacologic monitoring assessment in renal transplantation. Transplant. Proc. 1995; 27: 1064-5.